Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANAQUEST FORANE LABELING: VASODILATION ACTION

Executive Summary

ANAQUEST FORANE LABELING: VASODILATION ACTION should be included in labeling of the anesthetic agent, FDA's Anesthetic & Life Support Drugs Advisory Committee recommended at its Aug. 29 meeting. The group also recommended including statements that "coronary steal" (the diversion of blood flow from the myocardium) has been seen in animal models, but has not been conclusively shown in humans, and that evidence relating vasodilation to coronary steal and ischemia is inconclusive. The committee met to discuss labeling changes proposed by Anaquest. The Madison, Wisc.-based firm had proposed adding a discussion of the drug's vasodilation effects to the "Clinical Pharmacology" section of labeling. The firm also suggested including a statement that vasodilation can cause coronary steal. Anaquest suggested adding that with proper hemodynamic monitoring isoflurane can be safely used in patients with coronary artery disease. The firm further proposed including an indirect reference to ischemia, which would state: "Control of patient hemodynamics . . . is the most critical factor in preventing perioperative myocardial ischemia in patients with coronary artery disease." The committee initially voted against the proposed reference to ischemia, asserting that the statement was not specific to the drug. After presentations from FDA-invited speakers on current literature regarding the link between vasodilation and ischemia, the committee concluded that Forane labeling should note that some evidence, although inconclusive, supports the association. In a separate review, the committee recommended approval of Anaquest's Enlon Plus (edrophonium chloride, 10 mg per ml and atropine sulfate, 0.14 mg per ml), a pre-mixed combination of the two approved agents. Atropine, an anti-muscarinic, is frequently administered with edrophonium (Enlon) to counter its muscarinic (heart slowing) effect. The committee suggested a precautionary statement on the monitoring of heart rate be included in the package insert for Enlon Plus. Because atropine may initially slow the heart on administration, the committee recommended a statement cautioning physicians to evaluate initial heart rate before administration and to make preparations to manage the heart rate should slowing occur.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS014217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel